Matching articles for "TNKase"
In Brief: A New Indication for Tenecteplase (TNKase)
The Medical Letter on Drugs and Therapeutics • April 28, 2025; (Issue 1727)
The tissue plasminogen activator (tPA) tenecteplase
(TNKase – Genentech) has been approved by the FDA
for treatment of acute ischemic stroke in adults. It
is the second tPA to be approved in the US for...
The tissue plasminogen activator (tPA) tenecteplase
(TNKase – Genentech) has been approved by the FDA
for treatment of acute ischemic stroke in adults. It
is the second tPA to be approved in the US for this
indication; alteplase (Activase) was approved in
1996. Tenecteplase was approved in 2000 to reduce
the risk of death associated with acute ST-elevation
myocardial infarction (STEMI).
Tenecteplase (TNKase) for Thrombolysis
The Medical Letter on Drugs and Therapeutics • November 13, 2000; (Issue 1092)
Tenecteplase, a recombinant variant of human tissue plasminogen activator, is now available for thrombolysis in patients with acute myocardial...
Tenecteplase, a recombinant variant of human tissue plasminogen activator, is now available for thrombolysis in patients with acute myocardial infarction.